Effect of intravenous dexamethasone palmitate compared to dexamethasone on the duration of ropivacaine axillary brachial plexus block

INTERVENTION: Drug : Among patients scheduled for axillary brachial plexus and upper extremity surgery performed under general anesthesia under supervised general anesthesia at our hospital, patients with ASA class 1‐3 and those aged 19‐80 years are eligible. Once the patient arrives in the operating room, standard monitoring is performed. Patients receive 5‐6 L/min of oxygen using a simple facial mask and undergo a brachial plexus block under ultrasound guidance. After confirming the success of the brachial plexus block, sedation begins. Depending on the assignment to each group, lipothasone 8mg (same dose as dexamethasone 5mg) and dexamethasone 5mg are administered. CONDITION: Not Applicable PRIMARY OUTCOME: motor block duration sensory block duration SECONDARY OUTCOME: Analgesic consumption 24 and 48 hours after surgery Complications due to dexamethasone administration (infection or increased blood sugar) Complications related to postoperative nerve block procedure (general local anesthesia toxicity, paresthesia or nerve damage) Pain score at 8, 24, and 48 hours after surgery (NRS score) Patient satisfaction (7‐point Likert’s scale) QoR‐15 (Quality of recovery‐15) Quantity and quality of sleep on the day of surgery (numerical rating scale for sleep) Time to first analgesic intake after axillary brachial plexus block INCLUSION CRITERIA: * ASA physical status 1‐3 * Age: 19‐80 years * Patients with brachial plexus block and scheduled upper extremity surgery under supervised general anesthesia